Search clinical trials for: Placebo (sitagliptin)

Total 54296 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, France, Germany, Greece, India, Ireland, Japan, Korea, Republic of, Mexico, Philippines, Slovakia, Slovenia, Switzerland, Taiwan, Turkey, Ukraine
Boehringer Ingelheim

Completed

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Czech Republic, Estonia, Finland, France, Germany, Hungary, Latvia, Norway, Romania, Russian Federation, Slovakia, Spain, Ukraine
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Bulgaria, Czech Republic, Hungary, Poland
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

Type 2 Diabetes Mellitus
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

Type 2 Diabetes

China
Johnson & Johnson Consumer and Personal Products...

Completed

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

Androgenetic Alopecia

United States
AstraZeneca

Completed

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Type 2 Diabetes Mellitus

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Khoo Teck Puat Hospital

Completed

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Type II Diabetes in Subjects BMI 27 to 32

Singapore
Novartis
Genentech, Inc.; Tanox

Completed

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Allergic Asthma

United States
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)

Healthy

Egypt
AstraZeneca
Parexel

Completed

Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Germany
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

Type 2 Diabetes Mellitus
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type2 Diabetes Mellitus

Japan
GlaxoSmithKline

Completed

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Diabetes Mellitus, Type 2

United States
Merck Sharp & Dohme LLC

Completed

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Type 2 Diabetes Mellitus
University of British Columbia

Terminated

Sitagliptin in Cystic Fibrosis-Related Diabetes

Cystic Fibrosis

Canada
Boehringer Ingelheim

Completed

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Healthy
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator

Healthy Subjects
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC
Pfizer

Completed

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Type 2 Diabetes Mellitus
Sheikh Zayed Federal Postgraduate Medical Institute

Completed

Effect of Apple Cider Vinegar in Type 2 Diabetics

Diabetes Mellitus | Randomized Controlled Trial

Pakistan
Merck Sharp & Dohme LLC

Completed

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

Type 2 Diabetes Mellitus
Janssen Research & Development, LLC

Completed

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Diabetes Mellitus, Type 2

United States, Colombia, Mexico, Poland, Spain, India, Malaysia, Romania, South Africa, Sweden, Korea, Republic of, Estonia, Puerto Rico, Austria, Lithuania, Philippines, Guatemala, Iceland
Pfizer

Completed

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Hungary, Taiwan, Romania, India, South Africa, Philippines, Slovakia
Nicolai Jacob Wewer Albrechtsen

Completed

The Effects of Neprilysin on Glucagon-like Peptide-1 (NEP)

Heart Failure | Diabetes

Denmark
Merck Sharp & Dohme LLC

Completed

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Type 2 Diabetes Mellitus
IlDong Pharmaceutical Co Ltd

Recruiting

IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Type 2 Diabetes

Germany
Southern California College of Optometry at Marshall...

Recruiting

Eyelid Androgen Treatment in Dry Eye

Aqueous Tear Deficiency | Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)

United States
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects

Healthy Subjects

China
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

Type 2 Diabetes Mellitus
Vanderbilt University

Completed

Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome

Hypertension | Metabolic Syndrome

United States
Eli Lilly and Company

Terminated

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (IMPERIUM)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Germany, United Kingdom, Austria
AstraZeneca

Completed

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Puerto Rico, Taiwan, Australia
Merck Sharp & Dohme LLC

Completed

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Diabetes Mellitus, Type II
Hvidovre University Hospital
University of Copenhagen

Completed

Degradation of the Anorexic Hormone Peptide YY

Healthy

Denmark
Michael A. Nauck

Completed

Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion

Type 2 Diabetes

Germany
Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
Amsterdam UMC, location VUmc

Completed

Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome (SPHINX)

Diabetes Mellitus | Steroid Diabetes | Glucocorticoid-induced Diabetes | Beta-cell Function

Netherlands
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on to Basal Insulin in the Elderly

Diabetes Mellitus, Type 2

United States, New Zealand, Spain, Japan, Finland, Germany, Greece, Romania, South Africa, Denmark, Colombia, Poland, United Kingdom, Mexico, Australia, Belgium, Ireland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Australia, Canada, Denmark, Netherlands, Sweden
Boehringer Ingelheim

Completed

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

Diabetes Mellitus, Type 2

Argentina, Belgium, Canada, China, Germany, Korea, Republic of, Philippines, Russian Federation, Taiwan, Turkey, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Diabetes Mellitus, Type 2

Croatia, India, Israel, Italy, Malaysia, Netherlands, Poland, Romania, Slovakia, Thailand, Ukraine
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

Healthy Subjects
Emory University
Merck Sharp & Dohme LLC; University of Michigan; Temple University; Ohio University

Completed

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

Diabetes Mellitus, Non-Insulin-Dependent
University Hospital Tuebingen

Terminated

Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment (DapaSaxaBBIT)

Type 2 Diabetes

Germany

Search clinical trials for: Placebo (sitagliptin)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations